Skip to content
★ Sign in to follow
Total declarations
145
Companies
7
▲ Purchases (4 ops.)
€1.0M
▼ Sales (46 ops.)
€34.5M

Latest filing published 20 Jan 2026 for Phillips 66, €172k.

Filing timeline

BuySale
Glenn F. Tilton

Insider track record

Disclosed buys
4
Disclosed sells
46
Signal history

Closed purchases

Market purchases
4
Positive at T+90
75%
Median T+90
+1.0%

Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 29 Jun 2018 · 3054 days ago · €429k
    -21.2%
    Entry US$93.11 · Close at T+365 US$73.40
  • Filed 08 May 2014 · 4567 days ago · €357k
    -3.6%
    Entry US$83.54 · Close at T+365 US$80.54
  • Filed 27 Feb 2009 · 6463 days ago · €84k
    +5.5%
    Entry US$21.62 · Close at T+365 US$22.82
  • Filed 19 Sept 2007 · 6990 days ago · €165k
    +5.0%
    Entry US$26.12 · Close at T+365 US$27.42

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Glenn F. Tilton: trading record in brief

Glenn F. Tilton (board member) discloses dealings in 7 companies, chiefly United Airlines Holdings, Inc., Phillips 66 and Abbott Laboratories. We count 145 filings; the first trade dates from 30 December 2005 and the latest from 15 January 2026.

The open-market side counts 4 purchases for €1.0M alongside 46 sales for €34.5M. On balance, insiders were net sellers of €33.4M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 69 share grants and 13 option exercises.

In size, the median ticket on the buying side is €261k. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 75% of cases; the median change was +1.0%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 20 January 2026, the filings show a share grant worth €172k in Phillips 66. The clock since the last published purchase (29 June 2018) now reads 3,054 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Glenn F. Tilton

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations136 total
  • ◆
    DirectorExecutivesPhillips 66
    200,017 USD13SEC
    1,423 shares@ US$140.5618.8% of flowCommon StockSEC:0001194624-26-000002:0
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    1,203 shares0Common Stock, $0.01 par valueSEC:0001415889-25-012803:0
  • ◆
    DirectorExecutivesPhillips 66
    200,020 USD13SEC
    1,684 shares@ US$118.776921.3% of flowCommon StockSEC:0001534701-25-000024:0
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    1,322 shares0Common Stock, $0.01 par valueSEC:0001415889-24-012520:0
  • ◆
    DirectorExecutivesPhillips 66
    200,116 USD13SEC
    1,524 shares@ US$131.3120.1% of flowCommon StockSEC:0001534701-24-000023:0
  • ●
    DirectorExecutivesPhillips 66
    3,658 USD11SEC
    39.756 shares@ US$92.01570.4% of flowCommon StockSEC:0001534701-23-000109:0
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    1,450 shares0Common Stock, $0.01 par valueSEC:0001415889-23-007677:0
  • ◆
    DirectorExecutivesPhillips 66
    200,008 USD13SEC
    1,929 shares@ US$103.68520.3% of flowCommon StockSEC:0001534701-23-000018:0
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    1,421 shares0Common Stock, $0.01 par valueSEC:0001179110-22-002932:0
  • ◆
    DirectorExecutivesAbbott Laboratories
    0SEC
    1,602 shares0Common shares without par valueSEC:0001415889-22-004558:0
  • ◆
    DirectorExecutivesPhillips 66
    0SEC
    22,500 sharesCommon StockSEC:0001534701-22-000086:0
  • ◆
    DirectorExecutivesPhillips 66
    200,010 USD13SEC
    2,284 shares@ US$87.5719.2% of flowCommon StockSEC:0001534701-22-000006:0
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    1,681 shares0Common Stock, $0.01 par valueSEC:0001179110-21-005208:0
  • ◆
    DirectorExecutivesPhillips 66
    200,038 USD12SEC
    2,771 shares@ US$72.199.2% of flowCommon StockSEC:0001534701-21-000025:0
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    2,333 shares0Common Stock, $0.01 par valueSEC:0001179110-20-005787:0
  • ◆
    DirectorExecutivesAbbott Laboratories
    0SEC
    1,974 shares0Common shares without par valueSEC:0001179110-20-005190:0
  • ◆
    DirectorExecutivesPhillips 66
    200,082 USD12SEC
    1,907 shares@ US$104.9214.2% of flowCommon StockSEC:0001534701-20-000021:0
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    2,419 shares0Common Stock, $0.01 par valueSEC:0001179110-19-005674:0
  • ◆
    DirectorExecutivesAbbott Laboratories
    0SEC
    2,241 shares0Common shares without par valueSEC:0001179110-19-005303:0
  • ◆
    DirectorExecutivesPhillips 66
    200,070 USD12SEC
    2,155 shares@ US$92.8412.2% of flowCommon StockSEC:0001534701-19-000016:0
  • ▲
    DirectorExecutivesAbbVie Inc.
    496,260 USD31SEC
    5,400 shares@ US$91.90100.0% of flowCommon Stock, $0.01 par valueSEC:0001179110-18-009131:0
    Canonical exit: 25 Sept 2018 (T+90)
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    1,899 shares0Common stock, $0.01 par valueSEC:0001179110-18-006410:0
  • ◆
    DirectorExecutivesAbbott Laboratories
    0SEC
    2,945 shares0Common shares without par valueSEC:0001179110-18-006032:0
  • ◆
    DirectorExecutivesPhillips 66
    200,050 USD12SEC
    1,923 shares@ US$104.0310.1% of flowCommon StockSEC:0001534701-18-000020:0
  • ◆
    DirectorExecutivesAbbVie Inc.
    0SEC
    2,770 shares0Common stock, $0.01 par valueSEC:0001179110-17-006930:0

25 of 136 declarations